Report cover image

Epigenetics Drugs & Diagnostic Technologies Market, By Type (Epigenetic Drugs (DNMT Inhibitors (Azacitidine, Decitabine), HDAC Inhibitors (Vorinostat, Romidepsin)), Epigenetics Diagnostic Technologies (DNA Methylation, ChIP Technology)), and By Region (No

Publisher Coherent Market Insights
Published May 24, 2022
Length 155 Pages
SKU # CMI17212440

Description

Epigenetics Drugs & Diagnostic Technologies Market, By Type (Epigenetic Drugs (DNMT Inhibitors (Azacitidine, Decitabine), HDAC Inhibitors (Vorinostat, Romidepsin)), Epigenetics Diagnostic Technologies (DNA Methylation, ChIP Technology)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Epigenetic is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of disease such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel the market growth during the forecasted period.
Key features of the study:
This report provides in-depth analysis of the Global Epigenetic Drugs and Diagnostic Technologies market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global Epigenetic Drugs and Diagnostic Technologies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Celgene Corporation, Chroma Therapeutics Ltd., Epigentek Group Inc., Eisai Co. Ltd., EnVivo Pharmaceuticals Inc., Base Genomics, and Oryzon Genomics, S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global Epigenetic Drugs and Diagnostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Epigenetic Drugs and Diagnostic Technologies market
Detailed Segmentation:
Global Epigenetic Drugs and Diagnostic Technologies Market, By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
Global Epigenetic Drugs and Diagnostic Technologies Market, By Region:
North America
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
U.S.
Canada
Latin America
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Type:
Epigenetic Drugs
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
DNA Methylation
ChIP Technology
By Country
North Africa
Central Africa
South Africa
Company Profiles
4SC AG *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Acetylon Pharmaceuticals, Inc.
Astex Pharmaceuticals Inc.
CellCentric Ltd.
Celleron Therapeutics Ltd.
Celgene Corporation
Chroma Therapeutics Ltd.
Epigentek Group Inc.
Eisai Co. Ltd.
EnVivo Pharmaceuticals Inc.
Base Genomics
Oryzon Genomics, S.A.
“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

155 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Type
Market Snippet, By Country
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Highlights
Product launch
PEST Analysis
Technological Advancements
Regulatory Scenario
Mergers and Acquisitions
Impact of COVID19 on market
4. Global Epigenetic Drugs and Diagnostic Technologies Market, By Type, 2017 - 2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
Epigenetic Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Epigenetics Diagnostic Technologies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
DNA Methylation
ChIP Technology
5. Global Epigenetic Drugs and Diagnostic Technologies Market, By Region, 2017 - 2028, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
U.S.
Canada
Latin America
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
Germany
U.K.
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
Market Size and Forecast, By Type, 2017 - 2028, (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
North Africa
Central Africa
South Africa
6. Competitive Landscape
Company Profiles
4SC AG
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Acetylon Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Astex Pharmaceuticals Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
CellCentric Ltd.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Celleron Therapeutics Ltd.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Celgene Corporation
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Chroma Therapeutics Ltd.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Epigentek Group Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Eisai Co. Ltd.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
EnVivo Pharmaceuticals Inc.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Base Genomics
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Oryzon Genomics, S.A.
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
7. Section
References
Research Methodology
About us and Sales Contact
*Browse 22 market data tables and 14 figures on “Epigenetic Drugs and Diagnostic Technologies Market - Global forecast to 2028”.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us